Overview

A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants

Status:
Completed
Trial end date:
2017-03-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics and safety of single- and multiple-dose of TAK-491 in healthy Chinese participants.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda
Treatments:
Azilsartan medoxomil